Comparative Pharmacology
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus PREVACID IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus PREVACID IV.
DEXLANSOPRAZOLE vs PREVACID IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.
Lansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of gastric parietal cells. This action is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion.
30 mg orally once daily for 4 weeks for healing of erosive esophagitis; maintenance therapy: 30 mg orally once daily for up to 6 months. For GERD: 30 mg orally once daily for 4 weeks.
30 mg intravenous infusion over 30 minutes once daily for up to 7 days; may switch to oral therapy when patient can tolerate oral intake.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Technetium Tc-99m medronate
"The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderate1-2 hours; clinical context: duration of acid suppression exceeds half-life due to binding to proton pumps
Terminal elimination half-life is approximately 1.5–2 hours in healthy individuals; however, the pharmacodynamic half-life (duration of acid suppression) is longer (up to 24 hours) due to accumulation in parietal cell canaliculi.
Renal: 0% unchanged; metabolites eliminated via urine (51%) and feces (48%)
Primarily hepatic metabolism via CYP2C19 and CYP3A4; approximately 75% excreted in urine as metabolites, with less than 1% as unchanged drug; about 20% eliminated in feces via bile.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Dexlansoprazole + Pamidronic acid
"The therapeutic efficacy of Pamidronic acid can be decreased when used in combination with Dexlansoprazole."